Jefferies Financial Group Inc. Has $410,000 Position in Bausch Health Cos Inc. (NYSE:BHC)

Key Points

• Jefferies Financial Group Inc. has significantly reduced its stake in Bausch Health Cos by 85.9%, selling 386,641 shares and retaining 63,359 shares worth approximately $410,000.
• Multiple institutional investors have modified their positions in Bausch Health, with a notable increase of 244.2% by SBI Securities Co. Ltd. in the first quarter.
• Director John Paulson acquired over 3.5 million shares of Bausch Health stock, increasing his ownership by 12.19% and reflecting insider confidence in the company.

Jefferies Financial Group Inc. decreased its position in shares of Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 85.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 63,359 shares of the company's stock after selling 386,641 shares during the quarter. Jefferies Financial Group Inc.'s holdings in Bausch Health Cos were worth $410,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Maple Rock Capital Partners Inc. raised its holdings in Bausch Health Cos by 156.7% during the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock worth $42,718,000 after purchasing an additional 3,235,100 shares during the last quarter. Compass Rose Asset Management LP lifted its holdings in Bausch Health Cos by 366.7% in the fourth quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock valued at $16,926,000 after buying an additional 1,650,000 shares during the period. Renaissance Technologies LLC boosted its stake in Bausch Health Cos by 1,761.5% in the fourth quarter. Renaissance Technologies LLC now owns 495,172 shares of the company's stock valued at $3,991,000 after acquiring an additional 468,572 shares during the last quarter. Bridgewater Associates LP boosted its stake in Bausch Health Cos by 113.7% in the fourth quarter. Bridgewater Associates LP now owns 501,912 shares of the company's stock valued at $4,046,000 after acquiring an additional 267,089 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Bausch Health Cos during the 4th quarter worth $2,015,000. 78.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BHC. Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Royal Bank Of Canada upped their price target on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd.

Insider Activity

In other Bausch Health Cos news, Director John Paulson bought 3,564,059 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was acquired at an average cost of $5.94 per share, with a total value of $21,170,510.46. Following the purchase, the director owned 32,791,702 shares in the company, valued at $194,782,709.88. This trade represents a 12.19% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders purchased 6,352,667 shares of company stock valued at $35,870,767. 8.05% of the stock is currently owned by insiders.

Bausch Health Cos Trading Up 0.2%

Shares of BHC stock traded up $0.01 on Friday, hitting $5.77. The stock had a trading volume of 843,013 shares, compared to its average volume of 1,445,792. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. Bausch Health Cos Inc. has a twelve month low of $4.25 and a twelve month high of $9.85. The company has a fifty day moving average price of $6.10 and a two-hundred day moving average price of $6.03. The firm has a market cap of $2.14 billion, a P/E ratio of 22.19 and a beta of 0.41.

Bausch Health Cos (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The business had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. As a group, analysts forecast that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Cos Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.